GUJTHEM
Gujarat Themis Biosyn Limited (gujthem) Q1 FY27: Topline Surges 22%, PAT Improves 22%
Gujarat Themis Biosyn Limited (GUJTHEM) reports a 22% year-on-year topline surge to Rs. 43.8 crores in Q1 FY27.
Gujarat Themis Biosyn Limited (GUJTHEM) has reported robust financial results for Q1 FY27, marking a significant growth trajectory for the company. The topline surged 22.1% year-on-year to Rs. 43.8 crores, driven by healthy sales volumes and stable demand in the market. The company’s profit after tax (PAT) also improved by 22.1% to Rs. 11.1 crores, reflecting strong operational performance and improved margins.
Strategic Acquisitions Boost Growth
GUJTHEM’s strategic acquisitions have played a crucial role in its growth. The acquisition of MicroBiopharm in Japan, valued at JPY 21.5 Bn (~INR 1,300 Crore), is expected to broaden the company’s therapeutic coverage and enhance its manufacturing capabilities. Additionally, the agreement with Sanofi to acquire select product portfolios for ~EUR 158 Mn provides immediate global market access and established brand equity.
Operational Highlights
The company’s EBITDA increased by 49.4% to Rs. 20.8 crores, driven by economies of scale due to higher volumes. The EBITDA margin improved significantly, reflecting the company’s efficient operational model. The earnings per share (EPS) for the quarter stood at Rs. 1.02, indicating strong shareholder value creation.
GUJTHEM continues to focus on expanding its global footprint and technological capabilities. The development of new R&D and API units, along with the completion of a new fermentation facility, positions the company for sustained growth and operational efficiency. The hybrid power plant in Gujarat is expected to reduce power costs and lower the company’s carbon footprint, supporting environmental sustainability.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Gujarat falls 10.7% over three months and has not found a floor yet. Industry-leading margins of 28.2% reflect exceptional pricing power and operational efficiency. Revenue contracts at 3.8% CAGR. That signals structural headwinds, not a short-term blip. Sellers drive 1.5x the volume of buyers. Furthermore, they controlled 16 of recent sessions versus 14 for buyers — a clear distribution signal. Revenue grows at 3.8% CAGR — a respectable pace. However, the stock drops 10.7% in three months without an obvious fundamental trigger. Sector-wide pressure or a valuation re-rating can persist for longer than expected. Therefore, there is no rush to step in. Check Fundamentals of Gujarat Themis Biosyn Limited.
GUJTHEM
Gujarat Themis Biosyn Limited Announces Strategic Acquisitions and Expansion Plans
Gujarat Themis Biosyn Limited (GUJTHEM) announces strategic acquisitions and expansion plans, including MicroBiopharm Japan and Sanofi’s product portfolio.
Gujarat Themis Biosyn Limited (GUJTHEM) has announced significant strategic acquisitions and expansion plans for FY27, marking a pivotal phase in its growth trajectory. The company has entered into agreements to acquire MicroBiopharm Japan and Sanofi’s select product portfolio, both of which are subject to regulatory approvals.
Acquisition of MicroBiopharm Japan
GUJTHEM has announced the acquisition of MicroBiopharm Japan Co. Ltd., a fermentation-based immunosuppressants and oncology APIs manufacturer. This acquisition, valued at JPY 9.5 Bn (INR 561.82 Crs), will enhance GTBL’s fermentation and precision biotech capabilities, expanding its product portfolio to include advanced biologics and novel modalities.
Acquisition of Sanofi’s Select Product Portfolio
GUJTHEM has also agreed to acquire Sanofi’s anti-tuberculosis and anti-infectives portfolio. This €158 mn deal will provide GTBL with a comprehensive portfolio of mature brands for treating tuberculosis and other infections, significantly expanding its market presence in Europe, the Middle East, and Africa.
Strategic Rationale and Future Growth
The acquisitions are expected to unlock immediate geographical expansion, forward integration, and margin enhancement. With a strong focus on Europe and Middle East & Africa, GUJTHEM aims to leverage its established brand equity and technological prowess to drive future growth.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Gujarat posts a 69.3% three-month gain, but softens in the last few weeks. Industry-leading margins of 28.2% reflect exceptional pricing power and operational efficiency. Revenue contracts at 3.8% CAGR. That signals structural headwinds, not a short-term blip. The stock gives back 5.0% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 69.3% in three months on 3.8% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Gujarat Themis Biosyn Limited.
GUJTHEM
Gujarat Themis Biosyn Limited (gujthem) Q4 FY26: Strong Revenue Growth, Margin Expansion, and Strategic Acquisitions
Gujarat Themis Biosyn Limited (GUJTHEM) reports Q4 FY26 results with 17% revenue growth, margin expansion, and strategic acquisitions.
Gujarat Themis Biosyn Limited (GUJTHEM) has reported its Q4 FY26 results, showcasing a robust financial performance with a 17% year-on-year revenue growth to Rs. 44.2 crores. The company’s EBITDA increased by 20.7% to Rs. 19.4 crores, while the PAT stood at Rs. 10.9 crores. The strong volume performance translated into higher revenue growth, which, coupled with operational efficiencies, successfully expanded the company’s margins. Moreover, GUJTHEM announced strategic acquisitions to bolster its growth trajectory.
Operational Highlights
The company’s top line grew significantly in Q4 FY26, driven by steady and resilient market demand. The operating leverage from higher volumes successfully offset rising manpower costs and other operating expenses, ultimately driving EBITDA margin expansion. The EPS for the quarter is Rs. 1.00, while that for the full year is Rs. 4.28.
Strategic Acquisitions
GUJTHEM has signed an asset purchase agreement for a portfolio of 13 brands from Sanofi, France. This move will give the company access to a wide distribution network in major overseas markets for these products, and increase its presence in TB and anti-infective therapy areas. Additionally, GUJTHEM has signed a share purchase agreement to acquire Japan-based MicroBiopharm Japan Co., Ltd., via a wholly owned subsidiary in Japan. This deal brings additional manufacturing muscle, R&D capabilities, biotech know-how, and access to key new customers and geographies into the company’s portfolio, furthering its expansion into a CDMO.
Future Outlook
GUJTHEM is complementing its organic growth with inorganic expansion initiatives. The company’s R&D spend was approximately 9% of the topline in FY26, and it is setting up a hybrid power plant in Gujarat for captive consumption. This wind-plus-solar plant will not only reduce power costs and dependence on the grid but also lower the company’s carbon footprint, supporting environmental sustainability.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Gujarat rises 9.8% over three months, with buying pressure holding steady. The PEG stands at 22.11 — severely stretched. Any earnings miss could trigger a sharp de-rating. Industry-leading margins of 30.0% reflect exceptional pricing power and operational efficiency. The stock holds at 57% of its 52-week range with RSI at 56. In other words, neither side has a clear edge right now. The stock rises 9.8% in three months on 9.7% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Gujarat Themis Biosyn Limited.
-
Basic Materials3 days agoThe Ramco Cements Limited (ramcocem) Wins Three Honours at Kyoorius Design Awards 2026
-
GAIL3 days agoGail (india) Limited Appoints Shri Manoj Kumar Sharma as Director (projects)
-
Basic Materials3 days agoSteel Authority of India Limited (sail) FY’27 Snapshot: Robust Financials and Production Metrics
-
COFORGE2 days agoCoforge Limited (NSE: Coforge) Expands Ai-powered Vehicle Lifecycle Intelligence Capabilities
-
Industrials3 days agoTirupati Forge Limited Secures Strategic Industrial License Under Indian Arms Act for Artillery Shell Manufacturing
-
GODREJPROP3 days agoGodrej Properties Limited (godrejprop) Constructs 24-metre-wide Government Road in Gurugram
-
PREMIERENE1 day agoPremier Energies Limited (premierene) Commissions India’s Largest Solar Cell Facility
-
Information Technology Services22 hours agoPersistent Systems Limited (persistent) Earns Databricks Brickbuilder Specialization for BFSI